138 related articles for article (PubMed ID: 11939399)
1. Relationship between differences in 16-, 14-, and 15-membered ring macrolides and Streptococcus pyogenes resistance.
Braga PC
Eur J Clin Microbiol Infect Dis; 2002 Feb; 21(2):146-8. PubMed ID: 11939399
[No Abstract] [Full Text] [Related]
2. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
Mazzariol A; Koncan R; Vitali LA; Cornaglia G
J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
[TBL] [Abstract][Full Text] [Related]
3. Erythromycin resistance in Streptococcus pyogenes in Italy.
Bassetti M; Manno G; Collidà A; Ferrando A; Gatti G; Ugolotti E; Cruciani M; Bassetti D
Emerg Infect Dis; 2000; 6(2):180-3. PubMed ID: 10756153
[TBL] [Abstract][Full Text] [Related]
4. [Resistance to macrolides in Streptococcus pyogenes].
Bellido JL; García-Sáenz JA; Manzanares MA; Gutiérrez Zufiaurre MN; García-Rodríguez JA
Rev Esp Quimioter; 1998 Sep; 11(3):196-204. PubMed ID: 9795305
[No Abstract] [Full Text] [Related]
5. Group A streptococci. Erythromycin resistance and penicillin tolerance.
Savoia D; Millesimo M; Dotti G; Milano F
Adv Exp Med Biol; 1997; 418():447-9. PubMed ID: 9331690
[No Abstract] [Full Text] [Related]
6. Antimicrobial susceptibility patterns and macrolide resistance genes of beta-hemolytic streptococci in Korea.
Uh Y; Jang IH; Hwang GY; Lee MK; Yoon KJ; Kim HY
Antimicrob Agents Chemother; 2004 Jul; 48(7):2716-8. PubMed ID: 15215133
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain.
García-Rey C; Aguilar L; Baquero F; Casal J; Martín JE
J Clin Microbiol; 2002 Aug; 40(8):2959-63. PubMed ID: 12149359
[TBL] [Abstract][Full Text] [Related]
8. Erythromycin resistance phenotypes in Swedish clinical isolates of group A streptococci.
Jasir A; Schalén C
Adv Exp Med Biol; 1997; 418():443-5. PubMed ID: 9331689
[No Abstract] [Full Text] [Related]
9. Rapid decrease in the prevalence of macrolide-resistant group A streptococci due to the appearance of two epidemic clones in Cantabria (Spain).
Oliver MA; García-Delafuente C; Cano ME; Pérez-Hernández F; Martínez-Martínez L; Albertí S
J Antimicrob Chemother; 2007 Aug; 60(2):450-2. PubMed ID: 17540676
[No Abstract] [Full Text] [Related]
10. Increased activity of 16-membered lactone ring macrolides against erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae: characterization of South African isolates.
Klugman KP; Capper T; Widdowson CA; Koornhof HJ; Moser W
J Antimicrob Chemother; 1998 Dec; 42(6):729-34. PubMed ID: 10052895
[TBL] [Abstract][Full Text] [Related]
11. Resistance to macrolides in Group A streptococci from the European section of Turkey: genetic and phenotypic characterization.
Akata F; Oztürk D; Tansel O; Tatman-Otkun M; Otkun M; Fitoussi F; Bingen E; Tugrul M
Int J Antimicrob Agents; 2002 Dec; 20(6):461-3. PubMed ID: 12458142
[TBL] [Abstract][Full Text] [Related]
12. [Disappearance of Streptococcus pyogenes macrolide resistance in an area of northeastern Italy: a possible link with rational long-acting macrolide consumption].
De Rosa R; Avolio M; Stano P; Modolo ML; Camporese A
Infez Med; 2009 Jun; 17(2):82-7. PubMed ID: 19602920
[TBL] [Abstract][Full Text] [Related]
13. Significant increase in the prevalence of erythromycin-resistant, clindamycin- and miocamycin-susceptible (M phenotype) Streptococcus pyogenes in Spain.
Alós JI; Aracil B; Oteo J; Gómez-Garcés JL;
J Antimicrob Chemother; 2003 Feb; 51(2):333-7. PubMed ID: 12562699
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and mechanisms of macrolide resistance in Streptococcus pyogenes in Santiago, Chile.
Palavecino EL; Riedel I; Berrios X; Bajaksouzian S; Johnson D; Kaplan E; Jacobs MR
Antimicrob Agents Chemother; 2001 Jan; 45(1):339-41. PubMed ID: 11120993
[TBL] [Abstract][Full Text] [Related]
15. Utilisation of macrolides and the development of Streptococcus pyogenes resistance to erythromycin.
Urbánek K; Kolár M; Cekanová L
Pharm World Sci; 2005 Apr; 27(2):104-7. PubMed ID: 15999920
[TBL] [Abstract][Full Text] [Related]
16. Macrolide-resistant group a streptococcus--now in the United States.
Huovinen P
N Engl J Med; 2002 Apr; 346(16):1243-5. PubMed ID: 11961156
[No Abstract] [Full Text] [Related]
17. Decrease of erythromycin resistance in group A streptococci by change of emm distribution.
Koh EH; Kim S; Lee NY
Jpn J Infect Dis; 2008 Jul; 61(4):261-3. PubMed ID: 18653965
[TBL] [Abstract][Full Text] [Related]
18. [Streptococcus pyogenes and resistance to macrolides: experience at Monza].
Minerva Pediatr; 1998; 50(1-2):XII-XIII. PubMed ID: 9658791
[No Abstract] [Full Text] [Related]
19. High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. Spanish Group for the Study of Infection in the Primary Health Care Setting.
Alós JI; Aracil B; Oteo J; Torres C; Gómez-Garcés JL
J Antimicrob Chemother; 2000 May; 45(5):605-9. PubMed ID: 10797081
[TBL] [Abstract][Full Text] [Related]
20. Rapid inversion of the prevalences of macrolide resistance phenotypes paralleled by a diversification of T and emm types among Streptococcus pyogenes in Portugal.
Silva-Costa C; Ramirez M; Melo-Cristino J;
Antimicrob Agents Chemother; 2005 May; 49(5):2109-11. PubMed ID: 15855540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
